Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | HYAL1 |
| Gene Name: | HYAL1 |
| Protein Full Name: | Hyaluronidase-1 |
| Alias: | Hyaluronoglucosaminidase-1;Lung carcinoma protein 1 |
| Mass (Da): | 48368 |
| Number AA: | 435 |
| UniProt ID: | Q12794 |
| Locus ID: | 3373 |
| COSMIC ID: | HYAL1 |
| Gene location on chromosome: | 3p21.3 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 19813 |
| Percent of cancer specimens with mutations: | 0.27 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | HYAL1 is an lysosomal hyaluronidase that hydrolyses 1->4 linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. Contradicting evidence suggests it may have a role in promoting or suppressing tumour progression, and blocking TGFB1-enhanced cell growth. It is known to be inactivated in most lung cancers by loss of heterozygosity or by homozygous deletion, but it can function as an oncogene in many cancers of the prostate and urinary tract, as well as squamous cell laryngeal carcinoma. |